183 related articles for article (PubMed ID: 27100772)
1. Characterization of Immunoglobulin A/G Responses During 3 Doses of the Human Papillomavirus-16/18 ASO4-Adjuvanted Vaccine.
Gonçalves AK; Giraldo PC; Farias KJ; Machado PR; Costa AP; de Souza LC; Crispim JC; Eleutério J; Witkin SS
Sex Transm Dis; 2016 May; 43(5):335-9. PubMed ID: 27100772
[TBL] [Abstract][Full Text] [Related]
2. Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix.
Ferreira Costa AP; Gonçalves AK; Machado PRL; Souza LBFC; Sarmento A; Cobucci RNO; Giraldo PC; Witkin SS
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2313-2317. PubMed ID: 30141308
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
[TBL] [Abstract][Full Text] [Related]
4. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine.
Schwarz TF; Kocken M; Petäjä T; Einstein MH; Spaczynski M; Louwers JA; Pedersen C; Levin M; Zahaf T; Poncelet S; Hardt K; Descamps D; Dubin G
Hum Vaccin; 2010 Dec; 6(12):1054-61. PubMed ID: 21157180
[TBL] [Abstract][Full Text] [Related]
5. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
7. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.
Scherpenisse M; Mollers M; Schepp RM; Meijer CJ; de Melker HE; Berbers GA; van der Klis FR
Hum Vaccin Immunother; 2013 Feb; 9(2):314-21. PubMed ID: 23149693
[TBL] [Abstract][Full Text] [Related]
8. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
9. First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions.
Van Keer S; Willhauck-Fleckenstein M; Pattyn J; Butt J; Tjalma WAA; Van Ostade X; Hens N; Van Damme P; Waterboer T; Vorsters A
J Clin Virol; 2019 Aug; 117():11-18. PubMed ID: 31129514
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
12. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.
Schwarz TF; Galaj A; Spaczynski M; Wysocki J; Kaufmann AM; Poncelet S; Suryakiran PV; Folschweiller N; Thomas F; Lin L; Struyf F
Cancer Med; 2017 Nov; 6(11):2723-2731. PubMed ID: 28984053
[TBL] [Abstract][Full Text] [Related]
13. Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study.
Namujju PB; Pajunen E; Simen-Kapeu A; Hedman L; Merikukka M; Surcel HM; Kirnbauer R; Apter D; Paavonen J; Hedman K; Lehtinen M
BMC Res Notes; 2014 Jul; 7():445. PubMed ID: 25011477
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
16. Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls.
Pasmans H; Schurink-Van't Klooster TM; Bogaard MJM; van Rooijen DM; de Melker HE; Welters MJP; van der Burg SH; van der Klis FRM; Buisman AM
Vaccine; 2019 Nov; 37(49):7280-7288. PubMed ID: 31575492
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
18. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
19. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.
Schwarz TF; Spaczynski M; Schneider A; Wysocki J; Galaj A; Perona P; Poncelet S; Zahaf T; Hardt K; Descamps D; Dubin G;
Vaccine; 2009 Jan; 27(4):581-7. PubMed ID: 19022320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
